Anna-Lise WilliamsonFRSSAf MASSAf is a Professor of
Virology at the
University of Cape Town.[1] Williamson obtained her PhD from the
University of the Witwatersrand in 1985. Her area of expertise is human papillomavirus, but is also known on an international level for her work in developing vaccines for
HIV. These vaccines have been introduce in phase 1 of clinical trial. Williamson has published more than 120 papers.[2]
Anna-Lise Williamson is the Director of University of the Cape Town vaccine Research group GLP. Her area of expertise and what she is best known for is
Human Papillomavirus and
HIV Vaccines.[1]
Awarded a Chair in Vaccinology 2008 (South African Research Chairs Initiative)
Head of World Health Organization human papillomavirus Labnet lab for the Africa Region
Joint Head of University of Cape Town, National Institute for communicable Diseases, and National health Laboratory Service Molecular Epidemiology Laboratory
Anna-Lise Williamson is the head of the HIV vaccine development and human papilloma research group at the University of Cape Town. There, Williamson and a team of over 30 people are developing vaccines for
HIV-1 subtype C virus. This strain is known to be the most Virulent,[6] and known to be the principle strain that leads to AIDS.The goal of the investigation is to create affordable and effective HIV-1 C vaccines,[7][8][9] that would increase the longevity of memory T cells and develop a more functional use of the CD4+ and CD8+ cell response.[2] Two vaccines have been selected to move forward in clinical trials. These vaccines are DNA vaccines and a modified vaccinia virus Ankara vaccine. The vaccines were developed as part of the
South African AIDS Vaccine Initiative (SAAVI).[2][6]
Selected publications
Anna-Lise Williamson has published over 120 papers. Her publications mainly consists of her area of expertise addressing HIV vaccine development, HIV virus, and HPV virus.
Shephard, Enid; Burgers, Wendy A.; Van Harmelen, Joanne H.; Monroe, James E.; Greenhalgh, Trish; Williamson, Carolyn; Williamson, Anna-Lise (2008). "A Multigene HIV Type 1 Subtype C Modified Vaccinia Ankara (MVA) Vaccine Efficiently Boosts Immune Responses to a DNA Vaccine in Mice". AIDS Research and Human Retroviruses. 24 (2): 207–217.
doi:
10.1089/aid.2007.0206.
ISSN0889-2229.
PMID18240963.The goal of this publication is to identify the prevalence and risk factors associated with HPV Infection, and HPV-16 antibody in the population of Southern Africa.
^Williamson, Carolyn; Rybicki, Edward; Morris, Lynn (2000). "Designing HIV-1 subtype C vaccines for South Africa". South African Journal of Science. 96 (6): 318–323.